Literature DB >> 17576804

Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver.

Matthew Wortham1, Maciej Czerwinski, Lin He, Andrew Parkinson, Yu-Jui Yvonne Wan.   

Abstract

Identification of genetic variation predictive of clearance rate of a wide variety of prescription drugs could lead to cost-effective personalized medicine. Here we identify regulatory genes whose variable expression level among individuals may have widespread effects upon clearance rate of a variety of drugs. Twenty liver samples with variable CYP3A activity were profiled for expression level and activity of xenobiotic metabolism genes as well as genes involved in the regulation thereof. Regulatory genes whose expression level accounted for the highest degree of collinearity among expression levels of xenobiotic metabolism genes were identified as possible master regulators of drug clearance rate. Significant linear correlations (p < 0.05) were identified among mRNA levels of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, MRP2, OATP2, P450 oxidoreductase (POR), and UDP-glucuronosyltranferase 1A1, suggesting that these xenobiotic metabolism genes are coregulated at the transcriptional level. Using partial regression analysis, constitutive androstane receptor (CAR) and hepatic nuclear factor 4 alpha (HNF4 alpha) were identified as the nuclear receptors whose expression levels are most strongly associated with expression of coregulated xenobiotic metabolism genes. POR expression level, which is also associated with CAR and HNF4 alpha expression level, was found to be strongly associated with the activity of many cytochromes P450. Thus, interindividual variation in the expression level of CAR, HNF4 alpha, and POR probably determines variation in expression and activity of a broad scope of xenobiotic metabolism genes and, accordingly, clearance rate of a variety of xenobiotics. Identification of polymorphisms in these candidate master regulator genes that account for their variable expression among individuals may yield readily detectable biomarkers that could serve as predictors of xenobiotic clearance rate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576804     DOI: 10.1124/dmd.107.016436

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  50 in total

1.  Epigenetic modification of histone 3 lysine 27: mediator subunit MED25 is required for the dissociation of polycomb repressive complex 2 from the promoter of cytochrome P450 2C9.

Authors:  Neal A Englert; George Luo; Joyce A Goldstein; Sailesh Surapureddi
Journal:  J Biol Chem       Date:  2014-11-12       Impact factor: 5.157

2.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

3.  The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Authors:  Robin E Pearce; Michael Cohen-Wolkowiez; Mario R Sampson; Gregory L Kearns
Journal:  Drug Metab Dispos       Date:  2013-06-27       Impact factor: 3.922

4.  Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.

Authors:  Junling Yang; Minxia M He; Wei Niu; Steven A Wrighton; Li Li; Yang Liu; Chuan Li
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

5.  CCAAT/enhancer-binding protein alpha (C/EBPalpha) and hepatocyte nuclear factor 4alpha (HNF4alpha) synergistically cooperate with constitutive androstane receptor to transactivate the human cytochrome P450 2B6 (CYP2B6) gene: application to the development of a metabolically competent human hepatic cell model.

Authors:  Marta Benet; Agustín Lahoz; Carla Guzmán; José V Castell; Ramiro Jover
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

Review 6.  Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism.

Authors:  John Y L Chiang
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-02       Impact factor: 4.481

7.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

8.  Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes.

Authors:  Ritu Rana; Yuping Chen; Stephen S Ferguson; Grace E Kissling; Sailesh Surapureddi; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2010-01-19       Impact factor: 3.922

9.  Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.

Authors:  Dongfang Yang; Robin E Pearce; Xiliang Wang; Roger Gaedigk; Yu-Jui Yvonne Wan; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2008-10-15       Impact factor: 5.858

10.  Genetic predictors of interindividual variability in hepatic CYP3A4 expression.

Authors:  Vishal Lamba; John C Panetta; Stephen Strom; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.